Industrial Technology Research Institute

National Health Research Institutes

Shin Kong Wu Ho Su Memorial Hospital

Bio Preventive Medicine Corp.

Tzu-Ling Tseng

Wei-Ya Lin

Ping-Fu Cheng

Mary Ya-Ping Yeh

Hung-Yi Li

Yi-Ting Chen

Tsai-Wei Hsu

Yen-Peng Li

Yuh-Feng Ling

Jin-Shuen Chen

Ching-Fang Lu

Yi-Chen Liu

Angelina Huai-Lo Lee

Hong-Zen Yeh

Chwei-Shiun Yang

Chi-Ying Huang

Shih-Lan Hsu

Shih-Feng Tsai

Hui-Chu Hsieh

Pei-Hsiu Liao

Hou-Chang Chiu

Li-Jen Su

Yuh-Feng Lin

Giien-Shuen Chen

Described is a method of detecting a protein fragment in a urine sample and a serum sample. The protein fragment is a urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, or serum osteopontin fragment. The urine sample and the serum sample are obtained from the same individual.

Method of detecting a urine protein fragment and a serum protein fragment

Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and &#x3b2;-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing and staging liver fibrosis.

Biomarkers useful in liver fibrosis diagnosis

Identification of urokinase-type plasminogen, matrix metalloproteinase 9, and &#x3b2;-2-microglobulin as novel biomarkers associated with liver fibrosis and uses thereof in diagnosing liver fibrosis.

Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.

Biomarkers associated with nephropathy

Disclosed is use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.

Urine and serum biomarkers associated with diabetic nephropathy

The present invention provides a method for detecting liver fibrotic injury, including fibrosis and/or cirrhosis, by assaying biological samples for differential expression of at least one gene encoding a protein chosen from SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof, wherein differential expression of at least one gene suggests the presence of liver fibrosis or cirrhosis. The invention also provides a kit containing nucleic acid probes or antibodies for detecting liver fibrosis and/or cirrhosis by assaying the differential expression of proteins encoded by SEQ ID NO: 1-SEQ ID NO: 63 and human orthologs thereof.

Biomarkers for liver fibrotic injury

The present invention relates to methods of diagnosing myasthenia gravis in a subject, by determining an amount of at least one autoantibody that specifically binds one or more autoantigens selected from heat-shock protein 60 (hsp60), heat-shock protein 90, alpha isoform (hsp90&#x3b1;), and heat-shock protein 90, beta isoform (hsp90&#x3b2;). The invention also provides diagnostic kits for identifying a subject having myasthenia gravis.

Method of diagnosing myasthenia gravis and kits therefor

Growing community of inventors

Xinzhuang, Taiwan

Tzu-Ling Tseng